Trade Kintara Therapeutics, Inc. - KTRA CFD

Trading Conditions
Spread0.05
Long position overnight fee
Long position overnight fee

Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
-0.026179 %
(-US$1.05)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00


-0.026179%
Short position overnight fee
Short position overnight fee

Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
0.003957 %
(US$0.16)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00


0.003957%
Overnight fee time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin20
Stock exchangeUnited States of America
Commission on trade10%

Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. CloseN/A
Open0.38
1-Year Change-91.22%
Day's Range0.38 - 0.45

Kintara Therapeutics, Inc. Company profile

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.